uniQure N.V. (QURE)
| Market Cap | 1.14B |
| Revenue (ttm) | 16.10M |
| Net Income (ttm) | -198.97M |
| Shares Out | 63.03M |
| EPS (ttm) | -3.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 834,136 |
| Open | 17.94 |
| Previous Close | 17.90 |
| Day's Range | 17.81 - 18.89 |
| 52-Week Range | 8.73 - 71.50 |
| Beta | 0.75 |
| Analysts | Buy |
| Price Target | 45.00 (+149.31%) |
| Earnings Date | May 5, 2026 |
About QURE
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase ... [Read more]
Financial Performance
In 2025, uniQure's revenue was $16.10 million, a decrease of -40.64% compared to the previous year's $27.12 million. Losses were -$198.97 million, -16.94% less than in 2024.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for QURE stock is "Buy." The 12-month stock price target is $45.0, which is an increase of 149.31% from the latest price.
News
uniQure to Announce First Quarter 2026 Financial Results
~ uniQure to host earnings call on Tuesday, May 5, 2026 at 8:30 a.m. ET ~ LEXINGTON, Mass.
UNIQURE DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Encourages uniQure N.V.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In uniQure (QURE) To Contact Him Directly To Discuss Their Options
UNIQURE DEADLINE APPROACHING: Bragar Eagel & Squire, P.C. Encourages uniQure N.V.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In uniQure (QURE) To Contact Him Directly To Discuss Their Options
QURE SHAREHOLDER NOTICE: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data
Firm Reminds Investors of April 13 Lead Plaintiff Deadline in Pending Suit SAN FRANCISCO, March 30, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is updating its investigatio...
This biotech's stock is soaring after a ‘polarizing' FDA official is stepping down
Vinay Prasad, an official for the Food and Drug Administration, is reportedly stepping down, which is welcome news for biotech companies.
Federal health officials attacked an Amsterdam-based biotech company seeking approval of a Huntington's disease treatment and accused it of lying
Federal health officials, facing criticism from lawmakers for recent rejections of rare-disease drugs, attacked an Amsterdam-based biotech company seeking approval of a Huntington's disease treatment ...
FDA official calls UniQure's gene therapy a 'failed' treatment for Huntington's disease
UniQure needs to run another study to prove its gene therapy "actually helps people with Huntington's disease," a senior FDA official said. The official said UniQure is the "latest company to make a f...
Sr. FDA official calls Uniqure's Huntington's disease treatment a failure
A senior FDA official called Uniqure's experimental Huntington's disease treatment a "failed product" in a conference call with media members on Thursday, casting further doubt on the pr...
FDA Defends Call For Placebo Study In uniQure Huntington's Gene Therapy Trial
An official from the U.S. Food and Drug Administration (FDA) defended the agency's request for a new placebo-controlled study for uniQure N.V.'s (NASDAQ: QURE) experimental gene therapy for Huntington...
FDA official says UniQure fell short on Huntington's trial, defends new study request
UniQure's , trial design for its gene therapy for Huntington's disease did not offer sufficient proof that the drug slowed disease progression, a top U.S. Food and Drug Administration official said o...
These Analysts Cut Their Forecasts On uniQure Following Q4 Results
uniQure N.V. (NASDAQ: QURE) on Monday reported upbeat results for the fourth quarter.
uniQure Transcript: TD Cowen 46th Annual Health Care Conference
Phase I/II data for Huntington's showed significant slowing of disease progression and a strong safety profile, but FDA requires a new phase III trial due to concerns over post hoc analyses. Early results in epilepsy and Fabry programs are promising, with further data and regulatory discussions expected in 2024.
uniQure Earnings Call Transcript: Q4 2025
Full-year 2025 revenue declined to $16.1M, with a strong cash position of $622.5M supporting operations into 2029. AMT-130 for Huntington's disease showed robust 3-year efficacy data, but faces regulatory hurdles as the FDA requires a Phase III sham-controlled trial.
FDA tells UniQure study data insufficient for brain disorder therapy application
UniQure said on Monday the U.S. Food and Drug Administration has told the company that its data from an early-to-mid stage trial would not support a marketing application for its brain disorder gene t...
uniQure Announces 2025 Financial Results and Provides Recent Company Updates
~ Held Type A meeting with FDA to discuss AMT-130 for Huntington's disease; Company evaluating Phase III development considerations and plans to request follow-up Type B meeting in the second quarter ...
QURE INVESTOR REMINDER: uniQure N.V. Investors Have Until April 13, 2026 To Seek Lead Plaintiff Role
NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your uniQure N.V. (“uniQure” or the “Company”) (NASDAQ:QURE) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigat...
uniQure to Announce 2025 Financial Results
~ uniQure to host earnings call on Monday, March 2, 2026 at 8:00 a.m. ET ~ ~ uniQure to host earnings call on Monday, March 2, 2026 at 8:00 a.m. ET ~
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure Lawsuit - QURE
NEW YORK, Feb. 19, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of uniQure N.V. (NASDAQ: QURE).
UniQure N.V. (QURE) Securities Fraud: Contact Berger Montague To Discuss Your Rights
Philadelphia, Pennsylvania--(Newsfile Corp. - February 18, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against uniQure N.V. (NASDAQ: Q...
UNIQURE N.V. (QURE) INVESTOR ALERT Investors With Large Losses in uniQure N.V.
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquir...
Early uniQure Fabry Trial Shows Lasting Enzyme Boost, Safety Watch
uniQure N.V. (NASDAQ: QURE) on Friday announced updated preliminary safety and exploratory efficacy data from 11 patients in its Phase 1/2a trial of AMT-191.
uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease
~ Supraphysiological expression of α-Gal A activity maintained for over a year in longest treated patient as of data cutoff date ~
uniQure Announces Type A Meeting Scheduled with FDA
LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,...
What's Going On With uniQure Stock On Tuesday?
uniQure NV (NASDAQ: QURE) stock has plunged around 31% over the last month, as per data from Benzinga Pro.
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years
- 94% of patients (51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained therapeutic benefit- ...